Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...